TNBC, a subtype characterized by the absence of ER, PR, and HER2 expression, poses challenges in treatment due to the lack of targeted therapies typically effective against hormone receptor-positive or HER2-positive breast cancers.[34] Studies investigating the association between breastfeeding and TNBC risk have shown mixed results. Here, ERBB2 is linked to breast cancer.